102 related articles for article (PubMed ID: 15079899)
1. [Estimation of the protective effect of the novel potential antiparkinsonian agent himantane against MPTP neurotoxicity].
Val'dman EA; Nerobkova LN; Voronina TA
Eksp Klin Farmakol; 2004; 67(1):7-10. PubMed ID: 15079899
[TBL] [Abstract][Full Text] [Related]
2. [Effect of a new antiparkinsonian drug himantane on monoamine oxidase activity].
Val'dman EA; Voronina TA; Aksenova LN; Buneeva OA; Medvedev AE
Eksp Klin Farmakol; 2003; 66(5):3-5. PubMed ID: 14650204
[TBL] [Abstract][Full Text] [Related]
3. [A comparative study of hemantane and amantadine effects on dopamine transporter expression in brain of normal and MPTP-treated C57BL/6 mice].
Zimin IA; Logvinov IO; Antipova TA; Kovalev GI
Eksp Klin Farmakol; 2011; 74(1):11-4. PubMed ID: 21476268
[TBL] [Abstract][Full Text] [Related]
4. [Effects of antiparkinsonian drug hemantane on the level and metabolism of biogenic monoamines in brain structures of C57BL/6 mice].
Abaimov DA; Zimin IA; Kudrin VS; Kovalev GI
Eksp Klin Farmakol; 2009; 72(1):64-7. PubMed ID: 19334515
[TBL] [Abstract][Full Text] [Related]
5. [Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
Nepoklonov AV; Kapitsa IG; Ivanova EA; Voronina TA; Val'dman EA
Eksp Klin Farmakol; 2012; 75(11):3-6. PubMed ID: 23323324
[TBL] [Abstract][Full Text] [Related]
6. [The effect of hemantane on the generative function and gonad morphology in rats].
Smol'nikova NM; Nemova EP; Sorokina AV; Val'dman EA; Durnev AD
Eksp Klin Farmakol; 2004; 67(6):45-7. PubMed ID: 15707015
[TBL] [Abstract][Full Text] [Related]
7. [Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
Kovalev GI; Salimov RM
Eksp Klin Farmakol; 2011; 74(5):3-5. PubMed ID: 21809690
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].
Katunina EA; Samoĭlova EV; Val'dman EA; Nerobkova LN; Voronina TA; Avakian GN
Eksp Klin Farmakol; 2004; 67(2):16-8. PubMed ID: 15188753
[TBL] [Abstract][Full Text] [Related]
9. [Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)].
Andiarzhanova EA; Val'dman EA; Kudrin VS; Raevskiĭ KS; Voronina TA
Eksp Klin Farmakol; 2001; 64(6):13-6. PubMed ID: 11871228
[TBL] [Abstract][Full Text] [Related]
10. [Effect of the novel aminoadamantane derivative A-7 on Parkinsonian syndrome induced by systemic administration of neurotoxin MPTP].
Nerobkova LN; Val'dman EA; Voronina TA; Markina NV; Sharkova LM
Eksp Klin Farmakol; 2000; 63(3):3-6. PubMed ID: 10934586
[TBL] [Abstract][Full Text] [Related]
11. [Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
Zimin IA; Kapitsa IG; Voronina TA; Kovalev GI
Eksp Klin Farmakol; 2010 Nov; 73(11):2-5. PubMed ID: 21254589
[TBL] [Abstract][Full Text] [Related]
12. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
[TBL] [Abstract][Full Text] [Related]
13. [The acute and subchronic effects of hemantane on [3H]-dopamine reuptake in rat striatal synaptosomes ex vivo].
Abaimov DA; Kovalev GI
Eksp Klin Farmakol; 2007; 70(4):11-4. PubMed ID: 18078034
[TBL] [Abstract][Full Text] [Related]
14. [Immunotropic activity of a potential antiparkinson agent himantane].
Nezhinskaia GI; Val'dman EA; Nazarov PG; Voronina TA
Eksp Klin Farmakol; 2001; 64(2):60-3. PubMed ID: 11548451
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study of the distribution of 3[H]-himantane in the brain structures and the thymus of rats].
Kovalev GI; Rodionov AP; Petrenko ES; Zolotarev IuA
Eksp Klin Farmakol; 2003; 66(3):50-2. PubMed ID: 12924235
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the prolonged immunotropic effect of the potential antiparkinson agent himantane].
Nezhinskaia GI; Val'dman EA; Nazarov PG; Sapronov NS
Eksp Klin Farmakol; 2003; 66(3):44-6. PubMed ID: 12924233
[TBL] [Abstract][Full Text] [Related]
17. [Effect of hemantane on bioelectric activity of brain in mice with MPTP-induced Parkinson syndrome].
Kapitsa IG; Kokshenev II; Nerobkova LN; Val'dman EA; Voronina TA
Eksp Klin Farmakol; 2013; 76(4):3-6. PubMed ID: 23762980
[TBL] [Abstract][Full Text] [Related]
18. Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) in mice.
Abdel-Wahab MH
J Biochem Mol Toxicol; 2005; 19(1):32-41. PubMed ID: 15736157
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Oida Y; Kitaichi K; Nakayama H; Ito Y; Fujimoto Y; Shimazawa M; Nagai H; Hara H
Brain Res; 2006 Apr; 1082(1):196-204. PubMed ID: 16515773
[TBL] [Abstract][Full Text] [Related]
20. [Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo].
Abaimov DA; Zimin IA; Kovalev GI
Eksp Klin Farmakol; 2008; 71(1):18-21. PubMed ID: 18365481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
